Bukwang Pharmaceutical Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
November 13, 2023 at 11:00 pm
Share
Bukwang Pharmaceutical Co., Ltd. reported earnings results for the third quarter and nine months ended September 30, 2023. For the third quarter, the company reported sales was KRW 20,252.9 million compared to KRW 49,643.69 million a year ago. Net loss was KRW 16,111.03 million compared to KRW 693.34 million a year ago. Basic loss per share from continuing operations was KRW 235 compared to KRW 10 a year ago. Diluted loss per share from continuing operations was KRW 235 compared to KRW 10 a year ago. Basic loss per share was KRW 235 compared to KRW 10 a year ago.
For the nine months, negative sales was KRW 0.00013 million compared to KRW 0.00049 million a year ago. Net loss was KRW 20,532.8 million compared to KRW 3,235.15 million a year ago. Basic loss per share from continuing operations was KRW 300 compared to KRW 47 a year ago. Diluted loss per share from continuing operations was KRW 300 compared to KRW 47 a year ago. Basic loss per share was KRW 300 compared to KRW 47 a year ago.
Bukwang Pharm Co Ltd is a Korea-based company principally engaged in the manufacture and sale of pharmaceutical products. The Company operates its business through two segments. The Medicines and Quasi-drugs segment mainly produces and distributes pharmaceutical products including antidiabetic agents, anemic medicines, thyroid parathyroid hormone drugs, antihistamines, epileptic drugs, bronchodilators, stomatitis drugs, anti-malignant tumors, gum nutrition, hepatitis treatments, targeted anticancer agents, and others. The Research and Development segment mainly researches and develops pharmaceutical products.